Kornimate/medical-research-clean huggingface dataset:
comparison of the increment of neuromuscular parameters in vegetarians and non-vegetarians

Conditions: Strength Training; Dietary Proteins; Muscle Strength; Hypertrophy

Summary: a strength training session promotes increased muscle sensitivity to protein synthesis, which lasts for 24 hours after its closure. recent studies have shown that the subsequent intake to the training session of approximately 20g or 0.24g / kg of high-quality protein in the same meal induces a plateau in this synthesis. thus, this study aims to compare the muscular strength between vegetarian and omnivorous athletes with adequate protein intake to reach this plateau. it will recruit 64 university sportsmen who have maintained vegetarian or omnivorous diet for at least 6 months, totalizing 32 individuals per group. after signing the term of consent, participants will be submitted to anthropometric and body composition assessment (via dexa), neuromuscular tests \[(ie, muscle strength - 1rm, peak torque of knee extensors (je), muscle thickness of je and cohort analysis (ancova) will be used in order to compare the results of the study, and to compare the results of the covariance analysis (ancova). the levels of the neuromuscular parameters between the groups, considering the initial values of the force and the initial muscular thickness as covariables, the other parameters will be presented in the form of mean and standard deviation or median, the differences will be considered significant for values of p \<0, 05. expected to find no differences in strength and muscle thickness between vegetarians and omnivores after adequate protein intake.


Eligibility criteria:
inclusion criteria: * be over the age of 19 and under 60; * have bmi \<30 kg / m²; * be vegetarian or omnivorous for at least 6 months; * have not exercised regularly for at least 6 months. * be available to practice bodybuilding at school of physical education, physiotherapy and dance, 2x / week, for 3 months, free (times to combine). exclusion criteria * be vegan, vegetarian lacto or vegetarian egg * be a carrier of chronic diseases; * present physical limitations or musculoskeletal problems, which contraindicate the performance of strength exercises; * failure to adhere to the proposed dietary modifications, relating to the adequacy of the portion of protein per meal, due to financial unfeasibility (low income condition); * use of protein or amino acid, caffeine or other thermogenic food supplements.
national survey on dyslipidemic patients

Conditions: Dyslipidemia

Summary: the purpose of this observational study is to describe the time to lipid-lowering drug implementation in the management of dyslipidemic patients, according to the cardiovascular risk level.


Eligibility criteria:
inclusion criteria: * diagnosis of dyslipemia made less than 2 years * treated by a lipid-lowering drug * agree to take part in the survey exclusion criteria: * patient included in a clinical trial

Keywords: time to lipid-lowering drug implementation dyslipidemic patients
low-dose ct - stage i testicular cancer

Conditions: Testicular Cancer

Summary: patients with primary germ cell cancer of the testicles confined to the testis can avoid adjuvant treatment by entering a surveillance protocol. in the surveillance protocol, patients are followed for up to ten years with serial computed tomography scans to detect recurrence. multiple ct scans expose patients to a significant amount of radiation, which may be associated with an increased risk of secondary malignancies. this study hypothesizes that low dose ct scans are as effective as standard dose ct scans in detecting disease recurrence in this setting and will significantly reduce radiation exposure in this group of patients.


Eligibility criteria:
inclusion criteria: * phase a: * newly diagnosed testicular germ cell testicular cancer (gct) with no clinical or tumour marker evidence of metastases * stage i disease according to uicc stage groupings and currently on surveillance (in year 1 of non-seminoma surveillance or year 1 or 2 of seminoma surveillance) * ecog performance status 0 or 1 * phase b: * stage i disease according to uicc stage groupings * initial low dose ct considered by study radiologist to be of sufficient quality to allow surveillance using ldct protocol exclusion criteria: * any medical conditions that render the patient ineligible to undergo the protocol or procedure

Keywords: testicular cancer low-dose ct ct scan
phase 1 study to compare the pharmacokinetic characteristics and food effect of pelubiprofen (30mg) tablet ir and pelubiprofen sr (as a pelubiprofen 45 mg) tablet in healthy subjects

Conditions: Healthy Males

Summary: part 1 : a randomized, open label, multiple doses, cross-over, phase i trial to investigate the pharmacokinetics of pelubiprofen ir (pelubiprofen 30mg) tid and pelubiprofen sr (pelubiprofen 45 mg) bid in healthy male volunteers part 2 : a randomized, open label, single dose, cross-over, phase i trial to investigate the food effect of pelubiprofen sr (pelubiprofen 45 mg) in healthy male volunteers


Eligibility criteria:
inclusion criteria: * adult healthy males aged 20\~40 years * bmi valued over 19 kg/m2, below 27 kg/m2 * subjects whose blood pressure ; systolic bp over 90mmhg below 140mmhg, diastolic bp over 60mmhg below 90mmhg, stable station pulse over 45 bpm below 100 bpm * subjects who agree with double protective contraception or able to certificate already sterilization operation 1 day before administration of investigational new drugs within 14 days after completion * subjects who voluntarily agreed with written consent exclusion criteria: * subjects with clinically significant disease or past medical history in hepatic, renal, gi tract, respiratory, musculoskeletal, endocrine, neuropsychiatry, blood tumor and cardiovascular system * subjects with gi tract disease (eg. crohn's disease, peptic ulcer etc.) or surgery (except appendectomy and herniotomy) influence on administration investigational new drugs * subjects with hypersensitivity reaction or clinically significant disease in drugs (aspirin, nsaid anti-inflammatory agents and antibiotics) including pelubiprofen and food
prevalence and association of anxiety and sleep disturbances among medical students.

Conditions: Sleep Disturbances; Anxiety

Summary: observational, cross-sectional study

it was a cross-sectional study conducted in december 2024 with the consent of 200 undergraduate medical students of a tertiary care hospital affiliated medical college, who qualified as per the inclusion criteria. inclusion criteria: all the students of mbbs phase-ii. exclusion criteria: students with prior diagnosed sleep disorders students with prior diagnosed co-morbidities students unable/unwilling to answer the question.

Eligibility criteria:
inclusion criteria: - all the students of mbbs phase-ii. exclusion criteria: * students with prior diagnosed sleep disorders * students with prior diagnosed co-morbidities * students unable/unwilling to answer the question.

Keywords: sleep disturbances. anxiety medical students pittsburgh sleep quality index (psqi) beck anxiety inventory (bai) sleep quality
alpha lipoic acid effect on no-reflow phenomenon

Conditions: No-Reflow Phenomenon

Summary: prospective, randomized, open-label, controlled clinical trial to evaluate the efficacy and tolerability of alpha lipoic acid administration on oxidative stress, inflammatory markers, clinical outcome and occurrence of no-reflow in post myocardial infarction (mi) patients by assessment of aldehyde dehydrogenase-2 (aldh2) as a marker of oxidative stress and paraoxonase-1 (pon-1) as a marker of oxidative stress and inflammation.

all (70) stemi patients undergoing pci presenting to the cardiology department will be randomly assigned into one of 2 arms: 35 patients undergoing pci who will receive standard of care , the other 35 patients undergoing pci will receive standard of care in addition to alpha lipoic acid 600 mg daily for 4 week. iv alpha lipoic acid 600 mg once daily will be administered prior to pci then orally daily for 4 week after pci. baseline evaluation included demographics and history taking. after obtaining the informed consent, information including age, weight, height, smoking state, and other diseases e.g. hypertension, diabetes, hyperlipidemias, etc. will be documented for each patient. medication history in detail, as well as the background cardiovascular treatment, will be considered. all patients will be followed up regularly during the hospital stay and after discharge, will be assessed for the occurrence of adverse cardiac events and occurrence of adverse effects from medications

Eligibility criteria:
inclusion criteria: 1. female or male aged \>18 2. stemi patients undergoing pci exclusion criteria: 1. patients with a recent history of myocardial infarction (mi), a previous pci or a previous coronary artery bypass graft 2. a late presentation (\>12 h), unsuccessful primary pci (residual stenosis \>50% in the culprit lesion after procedure) 3. pretreatment with thrombolytic or glycoprotein iib/iiia inhibitor therapy before primary pci 4. infectious or inflammatory disease 5. severe liver or renal disease, (ast or alt \>3x uln or total bilirubin \>2.5 x uln), (crcl \< 60 ml/min (based on the cockroft-gault equation) 6. neoplasm, or hematological disorders 7. pregnant or breast-feeding patients 8. active participation in another clinical study 9. patients taking alpha lipoic acid. 10. systolic blood pressure \<90

Keywords: no-reflow phenomena alpha lipoic acid paraoxonase-1 aldehyde dehydrogenase-2 myocardial infarction
screening anal hpv colonization in men sex men using pre-exposure prophylaxis for hiv (anaprep'hpv)

Conditions: Pre-Exposure Prophylaxis

Summary: this is an interventional study investigating hpv carriage and liquid-based cytology at anal level. it will be offered to all patients undergoing prep consultations at besançon university hospital. the anal swab will be taken by the doctor using a cyto-brush during the consultation.

the duration of participation in the study is 3 months for the submission of the results of the samples. a medical proctology consultation may also be offered, depending on the results of the screening. this will be carried out in addition to the anal swabs taken quarterly to screen for other sexually transmitted infections. a questionnaire will be completed by the doctor to record the data of interest. from additional data already entered in the e-nadis software will be included for study.

Eligibility criteria:
inclusion criteria: men sex men using pre-exposure prophylaxis for hiv follow up au chu de besançon. exclusion criteria: * women * no msm * under 18 * history of hpv related cancer

Keywords: prep
evaluation of balance and trunk muscle endurance in dancers

Conditions: Balance; Distorted; Sports Injury

Summary: this study evaluates endurance of trunk muscles, balance and pulmonary functions in dancers. the participants will be evaluated trunk muscles endurance, pulmonary functions and balance which evaluated by computerized force plate system.

dance is a form of exercise associated with movements that require balance, flexibility, endurance and skill. in addition to maintaining balance, the endurance of the trunk stabilizer muscles has an important role in sport-specific activities, coordination and athletic performance. studies which conducted on dancers are mainly focused on abdominal muscle strength / endurance, lower extremity strength and physical performance. in the literature, it was reported that 40-84% of professional dancers and 26-51% of professional dancers had musculoskeletal injuries, particularly lower extremity problems. it is very important to regain balance after returning to the dance after foot and ankle injuries. considering the function of the trunk as a bridge between the lower and upper extremities, it is known that trunk muscles play a fundamental role in regaining balance. however, in the literature, there is no study showing the effects of trunk stabilizer muscles (abdominal, dorsal extensor, lateral flexor and diaphragm), trunk flexibility and dance-specific properties on balance in dancers. as a result of this study, it is aimed to show the effect of dance on balance and related parameters and to reveal the factors affecting the balance.

Eligibility criteria:
inclusion criteria: * able and willing to complete the informed consent process. * performing a sportive latin dancers as a competitive exclusion criteria: * having a pulmonary system disease * having a cardiac system disease * to do regular sports in addition to danc for the last three months

Keywords: balance dancer respiratory muscle trunk muscle
a rheumatoid arthritis study in participants on a background treatment of methotrexate

Conditions: Rheumatoid Arthritis

Summary: the primary purpose of this study is to help answer if ly2127399 is safe and effective in the treatment of rheumatoid arthritis while on a background treatment of methotrexate. this study is comprised of 3 periods: period 1: 52-week blinded treatment period 2: additional 48-week unblinded treatment period 3: 48-week post-treatment follow-up


Eligibility criteria:
inclusion criteria: * diagnosis of rheumatoid arthritis (ra) of more than 6 months and less than 15 years * regular use of methotrexate (mtx) in the past 12 weeks, with the dose being stable during the past 8 weeks * at least 8 tender and swollen joints * at least one erosion of a hand or foot joint observed on an x-ray * an abnormally high c-reactive protein (crp) level or erythrocyte sedimentation rate (esr) * positive for rheumatoid factor (rf) or anti-cyclic citrullinated peptide (ccp) antibody * woman must not be pregnant, breastfeeding, or become pregnant during the study exclusion criteria: * use of unstable doses of non-steroidal anti-inflammatory drugs (nsaids) in the past 6 weeks * steroid injection or intravenous (iv) infusion in the last 6 weeks * use of more than 10 milligrams/day (mg/day) of oral steroids in the last 6 weeks * history of an inadequate response to a biologic disease-modifying anti-rheumatic drug (dmard) * history of a serious reaction to other biological dmards * history of the use of rituximab or other b cell therapy * use of dmards other than mtx, hydroxychloroquine, or sulfasalazine within the last 8 weeks * use of leflunomide within the last 12 weeks (unless cholestyramine was used to speed up the elimination of leflunomide) * surgery on a joint or other major surgery less than 2 months ago, or plans to have joint surgery or major surgery during the study * active fibromyalgia, juvenile chronic arthritis, spondyloarthropathy, crohn's disease, ulcerative colitis, psoriatic arthritis, or other systemic inflammatory condition except ra * cervical cancer or squamous skin cancer within the past 3 years, or other cancer within the past 5 years * received a live vaccine received within the past 12 weeks (for example, vaccines for measles, mumps, rubella, and chicken pox, and nasal-spray flu vaccines) * hepatitis or human immunodeficiency virus (hiv) * a serious bacterial infection (for example, pneumonia or cellulitis) within 3 months or a serious bone or joint infection within 6 months * symptoms of herpes zoster or herpes simplex within the last month * active or latent tuberculosis (tb) * current symptoms of a serious disorder or illness * use of an investigational drug within the last month * history of the use of rituximab, any other b cell targeted biotherapy, or denosumab

Keywords: rheumatoid arthritis
the effects of vitamin d repletion in vitamin d deficient patients with stage 3 and 4 chronic kidney disease

Conditions: Chronic Renal Insufficiency; Proteinuria

Summary: a randomized clinical trial to determine if vitamin d repletion in ckd (chronic kidney disease) patients with low vitamin d levels will decrease proteinuria, a marker of kidney damage.

this rct will enroll 74 subjects, men and women over age of 18, with stage 3-4 ckd from various causes including diabetes and hypertension. patients will be recruited from the montefiore medical center nephrology clinics and the montefiore medical center internal medicine clinics and other interested individuals. informed consent will be obtained on all subjects. all subjects with meet with one of the investigators who will verbally explain to them the purpose of the study and the alternatives. blood and urine tests will be collected to assess for proteinuria, vitamin d levels, serum creatinine, calcium and phosphorus, as well as a urine albumin, calcium and creatinine. these tests will be used for experimental purposes only and will be collected at each study visit over the span of 6 months. there will be two arms, an arm randomized to 50000iu of ergocalciferol once weekly and a placebo arm for 3 months. for an additional 3 months, all patients will be repleted with vitamin d via open-label extension, based on their levels after 3 months. secondary outcomes include ambulatory blood pressure monitoring, hemoglobin a1c, homa-ir.

Eligibility criteria:
inclusion criteria: * age \>18 years * ability to provide informed consent * chronic kidney disease stage 3 and 4 * on ace inhibitor or arb for albuminuria if tolerated * assessed during eligibility screen: * albuminuria \>30 mg/g creatinine * 25(oh) vitamin d level \>12.5 and \<75 nmol/l exclusion criteria: * on vitamin d in past 4 weeks * plans to relocate out of new york city in the next 6 months * 25 (oh) vitamin d level \<12.5 nmol/l * hiv infection * history of hypercalcemia or kidney stones * serum phosphate \>5.5 mg/dl in past 3 months * serum calcium \>10.0 mg/dl in past 3 months * sbp \>160 dbp \>100 at screening visit * transplanted organ * cancer * polycystic kidney disease * rapidly deteriorating kidney function with the expectation for initiation of dialysis in less than 6 months

Keywords: vitamin d ckd proteinuria
bismuth-containing quadruple therapy for helicobacter pylori eradication

Conditions: Helicobacter Pylori Infection

Summary: the researchers collect treatment-naive h.pylori-positive patients from the outpatient clinic. the subjects were randomized to receive a 10-day or 14-day course of quadruple eradication therapy. 6-8 weeks after treatment, the subjects will re-take the 13c-urea breath test. calculate the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group.

the researchers collect treatment-naive h.pylori-positive patients from the outpatient clinic. if the subject meets the selection criteria but not the exclusion criteria, and signs an informed consent form, the researchers randomized the subjects in groups: subjects received a 10-day or 14-day course of bismuth-containing quadruple eradication therapy. the medication of groups are as follows. 6-8 weeks after the eradication treatment, the subjects will review the 13c-urea breath test, and the researcher records the results. after all subjects were tested, the eradication rates, adverse reaction rates, patient compliance and cost-effectiveness index of each group were calculated. according to the course of treatment, it is randomized into a 10-day treatment group and a 14-day treatment group. the two groups of bismuth quadruple regimens are the same, as follows: option 1: amoxicillin + clarithromycin + bismuth + vonoprazan fumarate option 2: amoxicillin + tetracycline + bismuth + vonoprazan fumarate option 3: amoxicillin + metronidazole + bismuth + vonoprazan fumarate three options are selected according to the hospital's situation.

Eligibility criteria:
inclusion criteria: * patients aged 18-65. * patients with h.pylori infection (positive for any of the following: h.pylori culture, histopathology test, rapid urease test, 13c/14c-urea breath test, stool h.pylori antigen test). * patients who have never received h. pylori eradication treatment. exclusion criteria: * patients with serious underlying diseases, such as liver insufficiency (aspartate aminotransferase or alanine aminotransferase greater than 3 times the normal value), renal insufficiency (cr≥2.0mg/dl or glomerular filtration rate \<50 ml/min), immunosuppression, malignant tumors, coronary heart disease or coronary artery stenosis ≥75%. * patients who are pregnant or lactating or unwilling to take contraceptive measures during the trial. * patients with active gastrointestinal bleeding. * patients with a history of upper gastrointestinal surgery. * patients allergic to treatment drugs. * patients with medication history of bismuth agents, antibiotics, proton pump inhibitor and other drugs within 4 weeks * patients with other behaviors that may increase the risk of illness, such as alcohol and drug abuse * patients whose re-check 13c/14c-urea breath test is negative before the start of the test. * patients who are unwilling or incapable to provide informed consents.

Keywords: helicobacter pylori bismuth-containing quadruple regimen
osteopathic visceral manipulation on functional constipation in obese adults

Conditions: Constipation - Functional

Summary: functional constipation in obese adults is a prevalent gastrointestinal issue characterized by infrequent bowel movements, difficulty during defecation, or a sensation of incomplete evacuation. obesity is a significant risk factor for functional constipation due to several physiological and lifestyle-related factors. excess body weight, particularly in the abdominal region, may exert pressure on the colon, leading to disrupted bowel function. additionally, dietary habits common among obese individuals, such as low fiber intake and inadequate hydration, can worsen constipation. sedentary lifestyles further contribute to reduced gastrointestinal motility. addressing functional constipation in obese adults requires a multifaceted approach, including dietary modifications to increase fiber and fluid intake, regular physical activity, and, in some cases, medical interventions to alleviate symptoms and improve quality of life.

visceral manipulation is a gentle manual therapy that focuses on the internal organs, particularly those within the gastrointestinal tract, to enhance their function and alleviate symptoms associated with various disorders. practitioners of visceral manipulation use their hands to apply specific, subtle forces to the affected areas, aiming to improve the mobility and motility of the organs. this technique is based on the premise that the body's organs are interconnected by fascia and ligaments, and any restriction or imbalance in these connections can lead to dysfunction and disease. by restoring the natural movement of these organs, visceral manipulation is believed to improve blood circulation, enhance digestive function, and reduce pain and discomfort associated with gastrointestinal disorders.

Eligibility criteria:
inclusion criteria: * patients diagnosed with functional constipation according to rome iv criteria * body mass index (bmi) ≥ 30 kg/m² * ability to provide informed consent exclusion criteria: * patients with organic gastrointestinal diseases, pregnancy or lactation * participation in another clinical trial within the last 30 days, endocrine and metabolic disorders (eg, hypothyroidism, hypercalcemia, diabetes mellitus, diabetes insipidus) * neurologic and psychiatric disorders (spina bifida, cerebral palsy, anorexia nervosa, known autism spectrum disorders) * secondary constipation to drug consumption, history of abdominal surgery